drugset
drugset / Trial / NCT05536726

A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

NCT05536726 ↗

Phase 3 Completed 458 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.

Timeline

Start
2023-01-07
Primary completion
2023-10-20
Completion
2024-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject 608 Monoclonal antibody 80 mg Subcutaneous
Subject 608 Monoclonal antibody 160 mg Subcutaneous

Indications

psoriasis